Free Trial

Bioqual Q4 2023 Earnings Report

Bioqual logo
$56.00 -1.50 (-2.61%)
As of 03:16 PM Eastern

Bioqual EPS Results

Actual EPS
-$0.79
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$16.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioqual Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Bioqual Earnings Headlines

BIOQUAL Announces Changes to Board of Directors
Most gold “analysts” aren’t really gold analysts… [watch out]
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
BIOQUAL Declares Dividend
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ) provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

View Bioqual Profile

More Earnings Resources from MarketBeat